The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant promise in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a greater substantial loss in body mass and improve metabolic markers, particularly